Compare ENTG & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTG | HOLX |
|---|---|---|
| Founded | 1966 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Medical Electronics |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 16.9B |
| IPO Year | 2000 | 1995 |
| Metric | ENTG | HOLX |
|---|---|---|
| Price | $132.42 | $76.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $127.80 | $77.89 |
| AVG Volume (30 Days) | 1.9M | ★ 8.6M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.55 | 0.79 |
| Revenue | $3,196,600,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $9.27 | $4.74 |
| Revenue Next Year | $9.48 | $5.03 |
| P/E Ratio | ★ $85.52 | $96.23 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $64.66 | $51.90 |
| 52 Week High | $142.50 | $76.07 |
| Indicator | ENTG | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 69.09 |
| Support Level | $107.76 | $75.10 |
| Resistance Level | $140.75 | N/A |
| Average True Range (ATR) | 5.81 | 0.19 |
| MACD | 1.86 | 0.03 |
| Stochastic Oscillator | 98.93 | 95.19 |
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.